^
    Back
    Association details:
    Biomarker:BRAF V600
    Cancer:Melanoma
    Drug:Braftovi (encorafenib) (BRAF inhibitor, cRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

    Excerpt:
    ...Written documentation of BRAF V600E mutation, or any other BRAF V600 mutation....
    Trial ID:
    NCT01436656
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ScienceDirect
    Title:

    BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAFV600E melanoma cells

    Published date:
    11/28/2020
    Excerpt:
    ...concurrent use of encorafenib and selective MCL-1 inhibitor can potentiate apoptosis in BRAFV600 melanoma and reduce the likelihood of developing drug resistance…
    Secondary therapy:
    S63845
    DOI:
    doi.org/10.1016/j.canlet.2020.11.036